Federal officials have announced an immediate reclassification of medical marijuana under national drug scheduling laws, moving it into a category with reduced restrictions.
The directive from the Trump administration marks a significant shift in how the United States handles cannabis policy at the federal level, representing what many consider a landmark change in the nation’s approach to marijuana regulation.
The rescheduling affects medical cannabis specifically, placing it under less stringent federal oversight than it previously faced under current classification systems.
